Unlock instant, AI-driven research and patent intelligence for your innovation.

Nitro adamantane-tetrazole compound, preparing method of nitro adamantane-tetrazole compound and application of nitro adamantane-tetrazole compound

The technology of a compound and tetrazolium, which is applied in the field of medicines for the treatment of diabetes, can solve the problems of undiscovered weight gain and the like

Active Publication Date: 2015-04-01
东营市广利临港产业园有限公司 +1
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinical results show that this type of drug has a good hypoglycemic effect, and no adverse reactions such as weight gain and hypoglycemia, which are common in other diabetes drugs, have been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nitro adamantane-tetrazole compound, preparing method of nitro adamantane-tetrazole compound and application of nitro adamantane-tetrazole compound
  • Nitro adamantane-tetrazole compound, preparing method of nitro adamantane-tetrazole compound and application of nitro adamantane-tetrazole compound
  • Nitro adamantane-tetrazole compound, preparing method of nitro adamantane-tetrazole compound and application of nitro adamantane-tetrazole compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Preparation of Compound I

[0020]

[0021] 2.10g (10mmol) compound II and 3.04g (30mmol) triethylamine were dissolved in 20mL of dry dichloromethane, stirred under ice-water bath cooling, then slowly added dropwise 2.42g (12mmol) compound III dissolved in 5mL of dry dichloromethane solution in methyl chloride. After the addition was complete, the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 200 mL of ice water, stirred, extracted with 50 mL×3 dichloromethane, the combined extracts were washed with saline, dried over anhydrous sodium sulfate, and then evaporated to dryness on a rotary evaporator, and the obtained residue was purified by column chromatography , the pure product of IV was obtained, white solid, ESI-MS, m / z=330 and 332 ([M+H] + ).

[0022] 1.97 g (6 mmol) of compound IV 0.68 g (6 mmol) of compound V, 1.00 g (6 mmol) of solid potassium iodide and 4.15 g (30 mmol) of solid potassium carbona...

Embodiment 2

[0024] Example 2 Preparation of Reference Compound D

[0025] In order to fully illustrate the beneficial effects of the compounds of the present invention, the applicant has recorded the following compound D (unpublished) found during the experiment as a pharmacodynamic reference compound.

[0026]

[0027] Its preparation method is as follows:

[0028]

[0029] 1.65g (10mmol) of compound II-1 and 3.04g (30mmol) of triethylamine were dissolved in 20mL of dry dichloromethane, stirred under cooling in an ice-water bath, and then slowly added dropwise 2.42g (12mmol) of compound III dissolved in 5mL of dry solution made in dichloromethane. After the addition was complete, the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into 200 mL of ice water, stirred, extracted with 50 mL×3 dichloromethane, the combined extracts were washed with saline, dried over anhydrous sodium sulfate, and then evaporated to dryness on a rotary evapor...

Embodiment 3

[0032] Example 3 Determination of the inhibitory effect of compounds on DPP-IV enzymes

[0033] Using the fluorescent DPP4 activity detection kit of BPS Bioscience Company, the inhibitory activity of the compound of the present invention on DPP-IV enzyme was determined.

[0034] Dilute the samples successively according to the concentration of 5, 10, 30, 100 and 200ng / kg, and add the samples in the following table in the fluorescence reaction 96-well plate:

[0035]

[0036] Place in a water bath at 22°C for 10 minutes, use a Spectra Max M5 fluorescence detector with an excitation light of 350nm, and measure the absorbance with 450nm fluorescence. Calculation of IC from the concentration-fluorescence intensity curve 50 values, the results are shown in the table below:

[0037] IC of compounds for inhibition of DPP-IV enzymes 50 value

[0038]

[0039] It can be seen from the above table that the compound of the present invention has a strong inhibitory effect on DPP-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of drugs related to the diabetes, in particular to a dipeptidyl peptidase-IV inhibitor comprising a nitro adamantane structure and a tetrazole-class structure, a preparing method of the dipeptidyl peptidase-IV inhibitor and an application of the dipeptidyl peptidase-IV inhibitor in preparing the drugs for the diabetes. The structure of the dipeptidyl peptidase-IV inhibitor is shown in the specification for the dipeptidyl peptidase-IV inhibitor.

Description

technical field [0001] The invention relates to the field of medicine related to diabetes. Specifically, the present invention relates to a dipeptidyl peptidase-IV inhibitor with a nitroadamantane tetrazole structure that has a therapeutic effect on diabetes, a preparation method thereof, a pharmaceutical composition containing them, and a method for treating diabetes Drug. Background technique [0002] According to statistics, there were approximately 250 million diabetic patients in the world in 2007, most of whom were type II (ie, non-insulin-dependent) diabetic patients. The antidiabetic drugs currently in clinical use mainly include sulfonylureas, metformin and insulin drugs. In recent years, insulin sensitizers and α-glucosidase inhibitors have also been marketed. These drugs have good therapeutic effects, but severe side effects such as hypoglycemia are common, and there are safety problems in long-term treatment, such as liver toxicity and weight gain. [0003] Di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D403/06A61P3/10
CPCC07D403/06
Inventor 蔡子洋
Owner 东营市广利临港产业园有限公司